Clinical trialPhase 1Not yet recruiting
Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Single-Agent KGX105 in Participants With Locally Advanced or Metastatic Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- August 2026
- Expected end
- November 2028
- Enrollment
- 85 participants
- Sites
- 1
- Primary outcomes
- Numbers of participants with adverse events(Phase Ia); Incidence of Dose-Limiting Toxicities (DLTs) during the DLT observation period.(Phase Ia); Number of participants with changes of clinical lab abnormalities(Phase Ia); The maximum tolerated dose of KGX105 monotherapy(Phase Ia); Objective Response Rate (ORR) of KGX105 monotherapy (Phase Ib)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 21 July 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.